Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Merck KGaA Distributes Voting Rights, Boosting Shareholder Confidence and Market Position

Merck KGaA’s routine voting‑rights distribution underlines strong governance while its oncology & vaccine pipeline, patent strategy and M&A plans signal continued growth and market‑access resilience.

Lisa Martinez

11/02/2026, 12:36

4 minutes to read

Eurofins Expands Bioanalytical Services & Boosts Share Repurchase for Growth & Shareholder Value

Eurofins Scientific expands GLP‑GCP bioanalytical services, boosting its clinical trial portfolio while executing a strategic share‑repurchase to support shareholder value and growth.

Lisa Martinez

11/02/2026, 04:41

3 minutes to read

How Astellas’ Mirabegron Settlement with Lupin Delays U.S. Generics & Boosts Revenue

How Astellas’ Mirabegron settlement with Lupin delays U.S. generics and protects $300 M in revenue.

Lisa Martinez

10/02/2026, 20:14

3 minutes to read

Waters Corp Q4 2025: Strong Revenue, BD Deal Boosts Diagnostics Growth

Waters Corp’s Q4 2025 earnings hit $1.05B, spurred by high‑throughput chemistry tools and a new Empower subscription model, while its $18B BD Biosciences deal positions it for future diagnostics growth—despite short‑term revenue dips.

Lisa Martinez

10/02/2026, 05:16

4 minutes to read

How AstraZeneca’s Pipeline and Pricing Strategy Drive Post‑Earnings Share Movements

Explore how AstraZeneca’s earnings, R&D pipeline, and market‑access strategies shape its valuation and future growth potential.

Lisa Martinez

09/02/2026, 15:40

5 minutes to read

How Eisai’s Strategic Partnerships Drive Growth in Japan’s Oncology Market

Explore how Eisai’s new co‑exclusive deals with Henlius and Fosun bolster its anti‑PD‑1 pipeline, mitigate patent cliffs, and aim for a 10‑15 % sales lift by 2029.

Lisa Martinez

09/02/2026, 10:13

4 minutes to read

Biogen Tackles Patent Cliffs, Cuts Costs, and Targets Alzheimer’s & Rare‑Disease Growth

Biogen’s Q4 2025 earnings reveal cost‑cutting tactics amid patent cliffs, a shift toward Alzheimer’s and rare‑disease drugs, and a focus on patient‑centric market access strategies.

Lisa Martinez

09/02/2026, 06:24

4 minutes to read

How Mettler‑Toledo’s Q4 2025 Earnings Reveal Pharma‑Style Growth & M&A Signals

Discover how Mettler‑Toledo’s Q4 rebound and growth strategy mirror pharma‑biotech dynamics—service expansion, innovation, and margin pressures.

Lisa Martinez

08/02/2026, 09:23

4 minutes to read

Gilead Sciences: Institutional Trades Signal Mixed Sentiment Amid Patent-Cliff Challenges

Institutional investors split on Gilead Sciences: European and Canadian funds buy while US large‑cap funds sell, reflecting differing views on patent cliffs, pipeline growth, and strategic M&A.

Lisa Martinez

07/02/2026, 13:37

5 minutes to read

Hikma Pharmaceuticals Faces Take‑over Rumors: Market Access, Patents and M&A Outlook

Hikma Pharmaceuticals faces takeover rumors; learn how its balanced branded/generic portfolio, patent‑cliff strategy, and M&A plans can shape market access and future growth.

Lisa Martinez

07/02/2026, 05:11

5 minutes to read

Newer articles